SG158112A1 - Hepatocyte growth factor (hgf) binding proteins - Google Patents

Hepatocyte growth factor (hgf) binding proteins

Info

Publication number
SG158112A1
SG158112A1 SG200908089-6A SG2009080896A SG158112A1 SG 158112 A1 SG158112 A1 SG 158112A1 SG 2009080896 A SG2009080896 A SG 2009080896A SG 158112 A1 SG158112 A1 SG 158112A1
Authority
SG
Singapore
Prior art keywords
hgf
binding proteins
growth factor
hepatocyte growth
activity
Prior art date
Application number
SG200908089-6A
Other languages
English (en)
Inventor
William M Winston
S Kirk Wright
May Han
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Arnold Horwitz
Original Assignee
Aveo Pharmaceuticals Inc
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc, Xoma Technology Ltd filed Critical Aveo Pharmaceuticals Inc
Publication of SG158112A1 publication Critical patent/SG158112A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
SG200908089-6A 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins SG158112A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21

Publications (1)

Publication Number Publication Date
SG158112A1 true SG158112A1 (en) 2010-01-29

Family

ID=38802077

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200908089-6A SG158112A1 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Country Status (21)

Country Link
US (5) US7649083B2 (de)
EP (2) EP2027156B9 (de)
JP (3) JP4686634B2 (de)
KR (1) KR101196060B1 (de)
AR (1) AR061171A1 (de)
AT (1) ATE495195T1 (de)
AU (1) AU2007254942B2 (de)
BR (1) BRPI0712222B1 (de)
CA (1) CA2654025C (de)
CY (1) CY1111714T1 (de)
DE (1) DE602007011923D1 (de)
DK (1) DK2027156T3 (de)
HK (1) HK1129395A1 (de)
IL (2) IL195037A (de)
MX (1) MX2008014829A (de)
NO (1) NO345476B1 (de)
NZ (1) NZ573818A (de)
PL (1) PL2027156T3 (de)
PT (1) PT2027156E (de)
SG (1) SG158112A1 (de)
WO (1) WO2007143090A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1648998T3 (pl) 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
DK2027156T3 (da) * 2006-06-02 2011-04-26 Aveo Pharmaceuticals Inc Hepatocytvækstfaktor (HGF)bindingsprotein
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
CA2691378A1 (en) 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer
US8044181B2 (en) 2007-11-30 2011-10-25 Kalobios Pharmaceuticals, Inc. Antibodies to the PcrV antigen of Pseudomonas aeruginosa
NZ588029A (en) * 2008-03-14 2012-12-21 Allergan Inc Immuno-based botulinum toxin serotype a activity assays
BRPI0912035A2 (pt) 2008-05-29 2017-05-23 Galaxy Biotech Llc anticorpo monoclonal, composição farmacêutica, uso de uma composição farmacêutica, mab de camundongo na forma quimérica ou humanizada, e, anticorpo humanizado
EP2842573B1 (de) 2008-11-07 2017-09-27 Galaxy Biotech, LLC Monoklonale Antikörper gegen den Fibroblasten-Wachstumsfaktor-Rezeptor 2
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP2013537966A (ja) 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法
PL3604339T3 (pl) 2011-01-14 2021-12-27 The Regents Of The University Of California Terapeutyczne przeciwciała przeciwko białku ror-1 i sposoby ich zastosowania
KR20140048276A (ko) 2011-07-15 2014-04-23 온코메드 파마슈티칼스, 인크. Rspo 결합제 및 이의 용도
EP2753357A1 (de) 2011-09-09 2014-07-16 Amgen Inc. Verwendung von c-met-protein zur vorhersage der wirksamkeit von anti-hepatocyten-wachstumsfaktor (hgf)-antikörpern bei patienten mit speiseröhren- und magenkarzinom
JP2014534949A (ja) 2011-09-19 2014-12-25 ジェネンテック， インコーポレイテッド Ｃ−ｍｅｔアンタゴニストおよびｂ−ｒａｆアンタゴニストを含む組合せ処置
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
WO2014166029A1 (zh) * 2013-04-07 2014-10-16 永卓博济(上海)生物医药技术有限公司 针对表皮生长因子受体的抗体
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
JP2017526356A (ja) * 2014-08-15 2017-09-14 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ１結合剤およびその使用
EP3193935A4 (de) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Behandlung von fibrotischen erkrankungen
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
EP4013869A1 (de) 2019-08-12 2022-06-22 InteRNA Technologies B.V. Neue behandlungen mit mirna-193a
WO2021170786A1 (en) 2020-02-28 2021-09-02 Interna Technologies B.V. miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH
JP2023539581A (ja) * 2020-08-28 2023-09-15 江蘇恒瑞医薬股▲ふん▼有限公司 ヘテロポリペプチドの末端異質性を低減するためのシグナルペプチド

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU1598801A (en) 1999-11-09 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The HGF-SF monoclonal antibody combinations
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
PL1648998T3 (pl) * 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
BRPI0611009A2 (pt) * 2005-06-02 2010-08-10 Galaxy Biotech Llc usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
DK2027156T3 (da) 2006-06-02 2011-04-26 Aveo Pharmaceuticals Inc Hepatocytvækstfaktor (HGF)bindingsprotein
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
NZ573818A (en) 2011-09-30
DK2027156T3 (da) 2011-04-26
US20100173362A1 (en) 2010-07-08
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
CA2654025C (en) 2016-08-02
IL219654A0 (en) 2012-06-28
EP2027156B1 (de) 2011-01-12
US9096664B2 (en) 2015-08-04
US8580930B2 (en) 2013-11-12
DE602007011923D1 (de) 2011-02-24
MX2008014829A (es) 2009-01-29
EP2027156A2 (de) 2009-02-25
PT2027156E (pt) 2011-04-18
US20110229462A1 (en) 2011-09-22
CY1111714T1 (el) 2015-10-07
US8273355B2 (en) 2012-09-25
JP5735476B2 (ja) 2015-06-17
AU2007254942A1 (en) 2007-12-13
US20140178935A1 (en) 2014-06-26
EP2361934A2 (de) 2011-08-31
JP2009539347A (ja) 2009-11-19
US20130203963A1 (en) 2013-08-08
JP2011072318A (ja) 2011-04-14
KR20090027226A (ko) 2009-03-16
BRPI0712222A2 (pt) 2012-01-10
EP2361934A3 (de) 2011-11-02
AU2007254942B2 (en) 2011-10-27
ATE495195T1 (de) 2011-01-15
BRPI0712222B1 (pt) 2021-10-13
JP2013090632A (ja) 2013-05-16
EP2027156B9 (de) 2011-03-30
US7943344B2 (en) 2011-05-17
WO2007143090A2 (en) 2007-12-13
US7649083B2 (en) 2010-01-19
KR101196060B1 (ko) 2012-11-01
NO20085421L (no) 2009-02-27
WO2007143090A3 (en) 2008-03-13
AU2007254942A8 (en) 2009-02-05
PL2027156T3 (pl) 2011-06-30
CA2654025A1 (en) 2007-12-13
US20080108565A1 (en) 2008-05-08
NO345476B1 (no) 2021-02-22
IL195037A (en) 2015-08-31
HK1129395A1 (en) 2009-11-27
JP4686634B2 (ja) 2011-05-25
IL195037A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
WO2008065378A3 (en) Binding members for interleukin-6
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2007015487A (es) Moleculas que son capaces de inhibir la union entre el factor de crecimiento de nervios y el receptor trka como analgesicos con efecto prolongado.
WO2011143318A3 (en) Anti-fgfr2 antibodies
MY185858A (en) Specific binding proteins and uses thereof
NZ606294A (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
WO2006014729A3 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2011328009A8 (en) Compounds and methods for treating pain
TW200833692A (en) Triazolopyridazine protein kinase modulators
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
HK1145070A1 (en) Therapeutic use of a growth factor, metrnl
MY160041A (en) Compositions and methods for treating parasitic infections
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
WO2013061083A3 (en) Therapeutic agents and uses thereof
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
EP2253305A3 (de) Hautbehandlung zur Porenverfeinerung
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina